<DOC>
	<DOCNO>NCT00821327</DOCNO>
	<brief_summary>The primary objective nonrandomized Phase II study evaluate objective response rate ( ORR , CR+PR ) patient advanced/metastatic UC treat combination gemcitabine , cisplatin , sunitinib .</brief_summary>
	<brief_title>Gemzar , Cisp , Sunitinib Urothelial Ca</brief_title>
	<detailed_description>Given strong preclinical rationale target angiogenesis urothelial carcinoma ( UC ) , evidence support co-targeting VEGFR2 PDGF , safety efficacy single-agent sunitinib patient UC , preclinical evidence synergy combination sunitinib cisplatin , evaluation sunitinib combination gemcitabine plus cisplatin previously untreated patient metastatic UC warrant .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Has histological documentation diagnosis transitional cell carcinoma ( TCC ) bladder , urethra , ureter , renal pelvis ( histology may mix , still require component TCC ; measurable disease ) 2 . Has unresectable metastatic disease 3 . Has Karnofsky Performance Status great equal 60 percent 4 . Is 18 year age old 5 . Has laboratory value define protocol 6 . Has resolution acute toxic effect prior chemotherapy radiotherapy surgical procedure NCI CTCAE ( v3.0 ) Grade le equal 1 7 . Has normal cardiac function evidence LVEF great equal 50 percent , determine multiple gated acquisition ( MUGA ) scan echocardiogram ( ECHO ) . The method must use throughout study evaluate LVEF . 8 . Has negative serum pregnancy test within 7 calendar day prior registration ( female patient childbearing potential [ surgically sterilize menarche 1 year postmenopausal ] ) 9 . Is currently breastfeed 10 . If fertile , patient ( male female ) agree use acceptable method birth control avoid pregnancy duration study period 3 month thereafter . 11 . Has sign Patient Informed Consent Form , Has sign Patient Authorization Form 1 . Has prior treatment systemic chemotherapy ( prior intravesical therapy permit ) 2 . Has major surgery radiation therapy within 4 week start study treatment 3 . Has NCI CTCAE ( Version 3.0 ) Grade 34 hemorrhage within 4 week start study treatment 4 . Has history know spinal cord compression , carcinomatous meningitis , evidence symptomatic brain leptomeningeal disease screen CT MRI scan . However treat , stable asymptomatic brain metastasis allow . 5 . Has follow within 6 month prior study drug administration : myocardial infarction , severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolism 6 . Has ongoing cardiac dysrhythmias NCI CTCAE ( Version 3.0 ) Grade 2 7 . Has prolong QTc interval baseline EKG 8 . Has uncontrolled hypertension ( grater 150/100 mm Hg despite optimal medical therapy ) 9 . Has preexist thyroid abnormality thyroid function maintain normal range medication 10 . Has know human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness active infection 11 . Is receive concomitant use investigational drug receive drug within 28 day prior registration 12 . Is receive concurrent treatment another clinical trial , include supportive care 13 . Has ongoing treatment therapeutic dos warfarin ( low dose warfarin 2 mg PO daily thromboembolic prophylaxis allow ) . Patients warfarin ( great 2mg ) thrombosis must switch low molecular weight heparin ( ie , Lovenox ) , prior registration protocol therapy . 14 . Is currently take drug proarrhythmic potential ( terfenadine , quinidine , procainamide , disopyramide , sotalol , probucol , bepridil , haloperidol , risperidone , indapamide flecainide ) within 7 day prior Day 1 Cycle 1 ( dose ) ( throughout study ) 15 . Is currently CYP3A4 inhibitor ( see Section 5 ) within 7 day prior Day 1 Cycle 1 ( dose ) , exception amiodarone , discontinue within 6 month prior Day 1 Cycle 1 ( dose ) 16 . Is currently CYP3A4 inducer ( see Section 5 ) within 14 day prior Day 1 Cycle 1 ( dose ) 17 . Has take herbal alternative medication within past 7 day refuse discontinue use herbal alternative therapy within 7 day prior Day 1 Cycle 1 ( dose ) 18 . Has serious uncontrolled intercurrent medical psychiatric illness , include serious infection 19 . Has history malignancy within last 5 year ( except cure basal cell carcinoma skin carcinoma situ uterine cervix ) , could affect diagnosis assessment study drug . 20 . Is pregnant nurse woman . Patients must surgically sterile postmenopausal , must agree use effective contraception period therapy . The definition effective contraception base judgment Study Investigator Treating Physician . Male patient must surgically sterile agree use effective contraception . Is unable comply requirement study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>